鼻咽癌患者放疗前后血清可溶性CD105变化及其临床意义

目的探讨鼻咽癌患者放疗前、后血清CD105水平的变化及其临床意义.方法采用酶联免疫吸附试验（ELISA）,对33例初治鼻咽癌患者放疗前、后2～3月,随访中出现复发转移及20例健康献血员血清中CD105的水平进行检测.结果初治鼻咽癌患者放疗前血清CD105水平明显高于健康对照组（P〈0.01）;与放疗前比较放疗后血清CD105水平明显降低（P〈0.01）;临床III＋IVa期鼻咽癌患者放疗前血清CD105水平明显高于健康对照组（P〈0.05）;鼻咽癌患者放疗前血清CD105水平在T、N及临床各分期间无显著性差异（P〉0.05）;经单因素分析显示：随访中出现复发转移患者其治疗前、后血清CD105水平均较未出现复发转移患者低（P〈0.01、P〈0.05）,放疗前CD105水平是影响预后的危险因素;经Logistic回归分析,N分期是影响鼻咽癌患者预后的危险因素（P〈0.05）,且N分期为N2＋N3的患者其发生复发转移的危险性是N分期为N0＋N1患者的8.975倍.结论血清CD105水平可以作为鼻咽癌患者治疗前、后病情监测及预后判断的一个新的检测指标.

Changes and Clinical Significance of Serum Levels of Soluble CD105 in Patients with Nasopharyngeal Carcinoma before and after Radiotherapy

Objective To study the changes and clinical significance of serum levels of soluble CD105 in nasopharyngeal carcinoma patients before and after radiotherapy.Method By enzyme linked immunosorbent assay（ELISA）,the serum levels of soluble CD105 were detected in 33 new nasopharyngeal carcinoma patients and patients who showed recurrence and metastasis in follow-up 3 months before and after radiotherapy,as well as in 20 healthy volunteers.Results The serum levels of soluble CD105 in new nasopharyngeal carcinoma patients before radiotherapy were obviously higher than those in healthy subjects（P〈0.01）,and those after radiotherapy（P〈0.01）.The serum levels of soluble CD105 in III＋Ⅳa stage nasopharyngeal carcinoma patients before radiotherapy was obviously higher than those in healthy subjects（P〈0.05）.There was no obvious difference in the serum levels of soluble CD105 among T stage,N stage and every clinical stage（P〉0.05）.Single factor analysis showed that the serum levels of soluble CD105 in patients who showed recurrence and metastasis in follow-up before and after radiotherapy were obviously lower than those in who did not show recurrence and metastasis（P〈0.01,P〈0.05）.The serum levels of soluble CD105 before radiotherapy affected the prognosis（P〈0.05）.Logistic regression showed that N stage was a risk factor influencing prognosis,and recurrence and metastasis risk of patients in N2＋N3 stage was 8.975 times than patients in N0＋N1 stage.Conclusion The serum levels of soluble CD105 can be used as a new index to monitor the changes of condition and judge the prognosis of nasopharyngeal carcinoma patients before and after radiotherapy.Serum should be more useful specimen to survey CD105 in circulation.